Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This study assessed the efficacy and safety of generic imatinib in patients with chronic
myeloid leukemia (CML) in Jordan. It was a multicenter, non-interventional, open-label,
prospective study combined with retrospective data collection from files of patients with a
diagnosis of Ph+ CML, treated with Cemivil (imatinib), where no visits or intervention(s)
additional to the daily practice were performed